Income from Sales Owned by Company, Percent

No definition available.

Name:	prgo_IncomefromSalesOwnedbyCompanyPercent
Namespace Prefix:	prgo_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=prgo_SteripodMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=prgo_ConsumerSelfCareAmericasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=prgo_MerckSharpDohmeLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=prgo_GenericProductAcquisitionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=prgo_BudesonideNasalSprayandTriamcinoloneNasalSprayMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=prgo_RXPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=prgo_BrandMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=prgo_DexsilMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=prgo_BrandedOTCRightsofPrevacidMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=prgo_ANDAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisitions and Divestitures - Acquisitions (Details) - USD ($) $ in Millions										1 Months Ended		3 Months Ended	12 Months Ended			24 Months Ended
	Dec. 31, 2020	Feb. 13, 2020	Jan. 03, 2020	Nov. 29, 2019	Jul. 02, 2019	May 17, 2019	Apr. 01, 2019	Aug. 24, 2018	May 29, 2018	Jan. 31, 2021	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Business Acquisition [Line Items]
Research and development													$ 177.7	$ 187.4	$ 218.6
Steripod
Business Acquisition [Line Items]
Purchase price paid			$ 26.0
CSCA \| Merck Sharp & Dohme License Agreement
Business Acquisition [Line Items]
Research and development									$ 50.0						$ 50.0
Developed product technology, formulations, and product rights \| Generic Product Acquisition
Business Acquisition [Line Items]
Purchase price	$ 16.4					$ 15.7
Weighted-average useful life (in years)						20 years						20 years
Developed product technology, formulations, and product rights \| Budesonide Nasal Spray and Triamcinolone Nasal Spray
Business Acquisition [Line Items]
Purchase price							$ 14.0
Weighted-average useful life (in years)							10 years
Income from sales owned by Company (percent)							100.00%
Developed product technology, formulations, and product rights \| RX \| Generic Product Acquisition
Business Acquisition [Line Items]
Purchase price					$ 49.0
Brand \| Dexsil
Business Acquisition [Line Items]
Purchase price		$ 8.0
Weighted-average useful life (in years)		25 years
Brand \| Steripod
Business Acquisition [Line Items]
Weighted-average useful life (in years)			25 years
Capitalized intangible assets			$ 25.1
Brand \| CSCA \| Branded OTC Rights of Prevacid
Business Acquisition [Line Items]
Purchase price				$ 61.5
Weighted-average useful life (in years)				20 years
Capitalized intangible assets				$ 61.7
ANDA
Business Acquisition [Line Items]
Research and development											$ 2.5					$ 0.7
ANDA \| Developed product technology, formulations, and product rights \| Generic Product Acquisition
Business Acquisition [Line Items]
Purchase price								$ 30.4
ANDA \| Developed product technology, formulations, and product rights \| RX \| Generic Product Acquisition \| Subsequent Event
Business Acquisition [Line Items]
Weighted-average useful life (in years)										20 years